Pharma Patent Exclusivity explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
Two pharmaceutical companies enter CIRP. Identical plants, identical capacity, comparable quality systems.
One is worth a multiple of the other — because its key patents have eight years to run and the other's expire next year.
In this sector the manufacturing asset is rarely the value driver. The exclusivity runway is.
Value turns on remaining exclusivity period, risk of generic entry, the pipeline of other proprietary products, and regulatory approvals. Physical plant is a commodity. A product approaching patent expiry commands a fraction of the value of one with years left, on identical assets.
The value drivers
1. Remaining exclusivity. A patent's economic value is concentrated in the period before generics arrive. The relevant measure is not the nominal term but the remaining runway — and how quickly revenue falls when that runway ends.
2. Generic entry risk. Exclusivity on paper is not exclusivity in fact. What matters is whether challengers have filed, whether the patent has been opposed or invalidated in any jurisdiction, and how hard the molecule is to make. A patent under credible challenge is worth substantially less than its remaining term implies.
3. The pipeline. Products in development, filings pending, and the research capability behind them. This is genuinely hard to value in a distressed company, because the pipeline's worth depends on continued investment that the debtor has probably stopped making — and on scientists who may already have left.
4. Regulatory approvals. Manufacturing approvals, product registrations and market authorisations are assets in their own right, and their transferability is the question. An approval that does not survive a change of ownership is worth far less than one that does.
Where these assets sit
Patents, product registrations and market authorisations are intangibles, which places them in the Securities or Financial Assets class — not with the plant. Securities and financial assets →
That allocation matters practically. The valuer registered for financial assets is the one who must handle patent portfolios and regulatory approvals, and they will need specialist input to do it — patent counsel on validity and challenge status, regulatory advisors on transferability.
And most of it will not be on the balance sheet. Internally developed patents appear only to the extent of capitalised development cost, which bears no relationship to their value. Intangibles under IBC →
Method
Discounted cash flow over the exclusivity period, with an explicit erosion curve after expiry, is the primary approach — because it directly models the thing that drives value.
The inputs that decide the answer:
- revenue by product, not in aggregate;
- remaining exclusivity for each;
- the post-expiry erosion assumption — typically steep, and worth sensitising hard;
- probability of early generic entry, product by product;
- continued investment required to maintain approvals and quality systems.
Relief-from-royalty works where products are licensed or comparable royalty rates exist. Relief-from-royalty →
The cost approach is close to meaningless here and should be used only as a labelled fallback. What a patent cost to develop tells you nothing about what it earns.
The distress adjustments
Pharma is unusually vulnerable to what insolvency does to a business:
- Quality systems degrade without investment, and a regulatory observation or import alert can destroy a market position quickly;
- Scientific staff leave, taking the pipeline's value with them;
- Approvals lapse where renewal filings are missed during the process;
- Distribution and prescriber relationships decay.
A valuation that projects historical revenue forward without modelling this overstates the answer. And where approvals have lapsed during the CIRP, that is a fact to be established rather than assumed either way. Assumptions and sensitivity →
Key takeaways
- Exclusivity runway, not plant capacity, drives value.
- Patents and approvals are financial-assets-class intangibles, not plant.
- A patent under credible challenge is worth less than its term suggests.
- Model revenue product by product, with an explicit erosion curve.
- Sensitise the post-expiry erosion assumption hard — it dominates the answer.
- Approvals may not survive a change of ownership. Establish transferability.
- The pipeline decays when investment stops and scientists leave.
Read next
- Valuation of Intangible Assets Under IBC
- Securities and Financial Assets Valuation Under IBC
- Relief-from-Royalty Method for Brand Valuation
- Obsolete Plant: When Physical and Income Valuations Diverge
Disclaimer: Positions stated as on 5 September 2026. Patent status and regulatory transferability are fact-specific — take specialist advice.